Missing/wrong data? Edit Wikidata item
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response
scientific article published in August 2016
Author/s
Work details
Publication date:
August 1, 2016
Language:
Unknown
Country of origin:
Unknown
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.